Skip to main content
Report this ad

See also:

Crohn's disease treatment trial now open to United States residents

Kathleen Blanchard wrote an article on regarding a new trial for people suffering with the autoimmune disease, Crohn's.

Qu Biologics has been testing Site Specific Immunomodulators (SSIs) agents for treating Crohn's disease in Canada. Now clinical trials are available in the United States.

The biological pharmaceutical company reopened clinical trials in the U.S because of so much interest, "said Dr. Hal Gunn, M.D. in a press release.

According to the company, 30 U.S. patients will be accepted into Phase 1/2 clinical trials to investigate the safety and efficacy of QBECO SSI for Crohn's disease. The trial is located in Vancouver, Canada.

“QBECO SSI aims to stimulate the innate immune system to remove the underlying trigger for this disease and therefore, presents a possible new treatment option for people living with Crohn’s disease, Dr. Gunn explains.

Ten patients treated for Crohn's disease reported improved symptoms. Seven patients had complete resolution after 3 months or more of treatment and four continued to experience remission after stopping QBECO SSI and all other medications.

Another result from the trial included three patients who reported Crohn's disease remission having been confirmed on colonoscopy and CT scan. The company notes all of the patients were treated under a "compassionate" use program versus a controlled blinded clinical trial, meaning the results don't prove the drug's effectiveness.

The drug was reported to be well tolerated among 121 patients with Crohn's and cancer.

The idea behind the Crohn's therapy is to boost the body's own immune system with the biological drug that to reverse inflammation that becomes chronic in cases of autoimmune diseases. The clinical trial information is here.


Please note: The numbers in this study are not scientifically valid; however, for people who are debilitated by Crohn's disease, you may be one of those helped.

Report this ad